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Accurate and efficient assessment of an animal’s blood glucose concentration aids clinical management of 
many pathological conditions that cause hyperglycemia 
or hypoglycemia, including diabetes mellitus. Most clini-
cians have access to laboratories with automated chem-
istry analyzers that quantify blood glucose concentration 
via a hexokinase or glucose oxidase reaction; however, 
the concentration can be measured several ways. Much 
less commonly, blood glucose concentration is quanti-
fied via photometric, oxidation-reduction, or measuring-
electrode techniques.1 Use of automated analyzers is the 
standard method for evaluating blood glucose concentra-
tion, but potential disadvantages include blood sample 
volume requirements and slow turnaround time.
Portable blood glucose meters are handheld instru-
ments that use reagent test strips to provide immediate 
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Objective—To compare blood glucose concentrations measured with 2 portable blood glu-
cose meters (PBGMs) validated for use in dogs (PBGM-D) and humans (PBGM-H) and an 
automated chemistry analyzer.
Design—Validation study.
Sample Population—92 samples of fresh whole blood and plasma from 83 dogs with 
various diseases.
Procedures—Each PBGM was used to measure whole blood glucose concentration, and 
the automated analyzer was used to measure plasma glucose concentration. Passing-
Bablok linear regression and Bland-Altman plots were used to determine correlations and 
bias between the PBGMs and the automated analyzer. Calculated acceptability limits based 
on combined inherent instrument imprecision were used with Bland-Altman plots to deter-
mine agreement. Clinical relevance was assessed via error grid analysis.
Results—Although correlation between results of both PBGMs and the standard analyzer 
was > 0.90, disagreement was greater than could be explained by instrument imprecision 
alone. Mean difference between PBGM-H and chemistry-analyzer values was −15.8 mg/dL. 
Mean difference between PBGM-D and chemistry-analyzer values was 2.4 mg/dL. Linear 
regression analysis revealed proportional bias of PBGM-H (greater disagreement at higher 
glucose concentrations); no proportional bias was detected for PBGM-D. No constant bias 
was detected for either PBGM. Error grid analysis revealed all measurements from both 
PBGMs were within zones without an anticipated effect on clinical outcome.
Conclusions and Clinical Relevance—Neither PBGM had exact agreement with the automat-
ed analyzer; however, the disagreement detected did not have serious clinical consequences. 
Our findings stressed the importance of using the same device for monitoring trends in dogs 
and using instrument-specific reference ranges. (J Am Vet Med Assoc 2009;235:1309–1313)
results. Most PBGMs are designed to use capillary blood 
by drawing the blood into the reaction chamber of the 
test strip by capillary action or having a drop of blood 
applied to the application zone of the test strip. The test 
strips contain a porous membrane that separates eryth-
rocytes so that analysis is performed on the resultant 
plasma.1 Because of the small sample volume required 
and the immediate results, PBGMs offer an important 
advantage relative to automated laboratory analyzers in 
the critical care setting. In addition, PBGMs allow home 
monitoring for better control of blood glucose concen-
tration in subjects with diabetes mellitus.
To date, the veterinary literature only contains 
data from the evaluation of human PBGMs; however, 
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in the past several years, several veterinary-specific PB-
GMs have entered the market.2,3 Therefore, the purpose 
of the study reported here was to compare results of 
PBGMs validated for use in animals or humans with 
those of a standard laboratory analyzer. All glucose-
measuring devices described in this report quantify and 
report a value for plasma glucose concentration. How-
ever, to maintain consistency among this report, clini-
cal jargon, and other literature on this topic, the term 
blood glucose will be used in place of plasma glucose.
Materials and Methods
Dogs—This prospective study was conducted with 
92 blood samples from 83 client-owned dogs with vari-
ous signalments and diseases. The need for a serum 
biochemical analysis was the only inclusion criterion. 
No dog for which such an analysis was performed was 
excluded.
Experimental protocol—Blood samples were ob-
tained from dogs in the order in which they were evalu-
ated. Samples were collected from a jugular, cephalic, 
or lateral saphenous vein with a 20- or 22-gauge needle 
and a syringe, and a drop of fresh whole blood was im-
mediately analyzed by use of each PBGM. The remain-
ing whole blood was transferred into tubes containing 
lithium heparina immediately after collection. Antico-
agulated blood was centrifuged and plasma was har-
vested within 15 minutes after collection.
The PBGMs were consistently operated in similar 
environmental conditions by the principal investigator 
or by a technician, in accordance with the manufactur-
er’s recommendations. Both PBGMs were calibrated per 
manufacturers’ instructions at the initiation of the study 
and upon use of each new container of test strips. Calibra-
tion included use of control solution and check test strips. 
Plasma glucose concentration was measured with the au-
tomated analyzer by licensed medical technologists.
Analyzers—The automated chemistry analyzerb 
measures glucose concentration via an enzymatic hexo-
kinase oxidase reaction, and results are detected spectro-
photometrically. The analyzer requires 40 µL of plasma 
or serum for each test; the linear range is 2 to 750 mg/dL.4 
Results are generated in approximately 6.5 minutes.
The PBGM-Hc makes use of a glucose dehydro-
genase reaction and reflectance photometry to detect 
blood glucose concentration. Operation of the glucom-
eter requires that 1 µL of whole blood be applied di-
rectly to the test strip. The manufacturer recommends 
use of capillary rather than venous blood. The linear 
range is 10 to 600 mg/dL, and results are obtained in as 
few as 5 seconds.5
The PBGM-Dd is validated for use in dogs and cats. 
It makes use of a glucose oxidase reaction and electro-
chemical biosensor technology. Operation of the glu-
cometer requires that 1 µL of whole blood be pulled 
into the chamber via capillary action. The manufactur-
er states that the PBGM-D is validated for both capillary 
and venous blood. The linear range is 10 to 600 mg/dL, 
and results are obtained in a mean of 9 seconds.6
Data analysis—Data were analyzed by use of com-
mercial medical statistics software.e The automated 
analyzer was used as a reference standard to which the 
PBGMs (index tests) were compared. Glucose values 
reported as high or low by the PBGMs were excluded 
for the purposes of the statistical analysis because only 
numerical values could be compared with results from 
the automated analyzer. Method comparison was con-
ducted as described elsewhere.7
Briefly, descriptive statistics were generated for 
each instrument. Bland-Altman difference plots were 
constructed for results of each PBGM, compared with 
results of the automated analyzer. Correlation coeffi-
cients (r) were calculated, and values were interpreted 
as follows: 0.90 to 1.00, very high correlation; 0.70 to 
0.89, high correlation; 0.50 to 0.69, moderate correla-
tion; 0.30 to 0.49, low correlation; and 0 to 0.29, little, 
if any, correlation.8 Precision data (CVs) for each in-
strument were obtained from the manufacturers of the 
instruments. For each PBGM, the combined inherent 
imprecision of the PBGM and the automated analyzer 








For each datum point, acceptance limits7 for the dif-
ference between instruments were calculated as follows:





If > 5% of the differences between PBGM and au-
tomated analyzer were outside of the calculated accep-
tance limits, the null hypothesis that the 2 methods are 
identical was rejected.
Passing-Bablok linear regression analysis was used 
to detect constant and proportional bias. If the 95% CI 
for the slope did not include the value of 1, this was 
considered evidence of proportional bias. If the 95% CI 
for the y intercept did not include the value of 0, this 
was considered evidence of constant bias. Overall per-
formance of each PBGM, as compared with that of the 
automated analyzer, was evaluated on the basis of cor-
relation, mean difference, and presence or absence of 
constant or proportional bias.
In addition, PBGM data were assessed for clinical 
relevance by use of error grid analysis, which focuses 
on the clinical relevance of error.9,10 The error grid di-
vided the plot of chemistry-analyzer values (x-axis) 
versus the PBGM values (y-axis) into 5 zones associ-
ated with the following 5 risk levels: zone A, no effect 
on clinical action; zone B, altered clinical action but no 
or minimal effect on clinical outcome; zone C, altered 
clinical action with a likely effect on clinical outcome; 
zone D, altered clinical action with considerable medi-
cal risk; and zone E, altered clinical action with dan-
gerous consequences. This specific error grid was de-
veloped by physicians, assuming a target blood glucose 
concentration between 70 and 180 mg/dL, with blood 
glucose values < 70 or > 240 mg/dL requiring inter-
vention.9,10 One hundred endocrinologists were given 
datum points of measured blood glucose values versus 
true blood glucose values for hypothetical patients and 
asked to classify the disagreement between values into 
1 of the 5 risk zones. The endocrinologists’ responses 
were averaged to create the error grid.















Blood samples from 63 dogs were evaluated for glucose 
concentration with both PBGMs in addition to the automated 
analyzer. Samples from an additional 29 dogs were evaluated 
with only the PBGM-D and the automated analyzer.
Blood glucose concentrations measured with the PBGM-
H ranged from 51 to 414 mg/dL, in addition to 1 H (high 
value) reading that corresponded to an automated-analyzer 
value of 685 mg/dL. Blood glucose concentrations measured 
with the PBGM-D ranged from 52 to 488 mg/dL, in addition 
to 1 H reading that corresponded to an automated analyzer 
value of 685 mg/dL. The correlation was very high between 
both PBGMs and the automated analyzer (PBGM-H, r = 0.99; 
PBGM-D, r = 0.93). Bland-Altman plot analysis revealed a 
mean difference of −15.8 mg/dL between the PBGM-H and 
the automated analyzer (Figure 1) and a mean difference of 
2.4 mg/dL between the PBGM-D and the automated ana-
lyzer (Figure 2). For both PBGMs, many values (70% for 
the PBGM-H and 47% for the PBGM-D) were outside of cal-
culated acceptability limits based on the combined inherent 
imprecision of the glucometer and automated analyzer. On 
the basis of these findings, results of neither PBGM was con-
sidered identical to those of the automated analyzer.
Passing-Bablok linear regression analysis of PBGM-H 
values versus automated analyzer values yielded a y-in-
tercept of 2.65 (95% CI, −5.64 to 9.94) and slope of 0.88 
(95% CI, 0.83 to 0.95). On the basis of these findings, 
proportional, but not constant, bias was considered to 
exist. Linear regression analysis of PBGM-D values ver-
sus automated analyzer values yielded a y-intercept of 
−11.14 (95% CI, −41.00 to 3.14) and slope of 1.09 (95% 
CI, 0.96 to 1.40). On the basis of these findings, neither 
constant nor proportional bias was considered to ex-
ist. Therefore, the only statistically apparent bias was 
that the PBGM-H had proportional bias, yielding lower 
values than the automated analyzer at higher glucose 
concentrations.
Error grid analysis revealed that all measurements 
for both PBGMs were within zone A (no effect on clini-
cal action) or zone B (altered clinical action but no or 
minimal effect on clinical outcome; Figure 3).
Figure 1—Bland-Altman difference plot of glucose concentrations 
measured with a PBGM-H and an automated chemistry analyzer 
in 63 samples of fresh whole blood and plasma from dogs with 
various diseases. Solid lines represent 0 ± (1.96 X CVBoth Methods X 
meanBoth Methods). The space between the solid lines represents the 
limits within which the difference between the 2 methods must 
fall for the 2 methods to be considered identical. The dotted line 
represents the mean difference between the 2 methods, with 
results of the PBGM-H averaging 15.8 mg/dL lower than results 
of the automated analyzer.
Figure 2—A Bland-Altman difference plot of glucose concentra-
tions measured with a PBGM-D and an automated chemistry 
analyzer in 92 samples of fresh whole blood and plasma from 
dogs with various diseases. The dotted line represents the mean 
difference between the 2 methods, with results of the PBGM-D 
averaging 2.4 mg/dL higher than results of the automated ana-
lyzer. See Figure 1 for remainder of key.
Figure 3—Results of error grid analysis for detection of type 1 
diabetes by use of blood glucose concentration values from 2 
PBGMs (PBGM-H, black squares; PBGM-D, white squares) and 
an automated chemistry analyzer as measured in 63 samples of 
fresh whole blood and plasma from dogs with various diseases. 
Zones A to E represent different consequences of an inaccurate 
glucose measurement: zone A, no effect on clinical action; zone 
B, altered clinical action without effect on clinical outcome; zone 
C, altered clinical action with an effect on clinical outcome; zone 
D, altered clinical action with possible considerable medical risk; 
and zone E, altered clinical action with possible dangerous con-
sequences.

















Portable blood glucose meters are rapidly sup-
planting benchtop chemistry analyzers for immediate 
determination of blood glucose concentrations in criti-
cal care and home environments. New and different PB-
GMs are constantly becoming available, making it chal-
lenging to choose an appropriate meter, and very few of 
these PBGMs are designed and validated specifically for 
use in animals.
The first goal of the study reported here was to de-
termine correlations between results of an automated 
analyzer and those of PBGMs. Correlation is a measure 
of association, rather than of agreement, between val-
ues.7 In this context, association refers to the fact that 2 
variables extend in the same direction, whereas perfect 
agreement refers to the fact that 2 methods yield the 
same numerical result. We found very high correlations 
between measurements of blood glucose concentration 
made by both PBGMs and the automated analyzer.
Our second goal was to assess agreement between 
results of the automated analyzer and the PBGMs (ie, 
how closely the values matched). Disagreement be-
tween 2 methods may be attributable to random error 
(imprecision) or systematic error (bias); bias can be 
classified as constant or proportional.7 Constant bias 
refers to results of one method that are consistently 
higher or lower than results of another method (eg, one 
method always yields results 20 mg/dL lower than the 
other). Proportional bias refers to a difference that is de-
pendent on the concentration or activity of the analyte 
in question.7 Every routinely used laboratory method 
(so-called field method) has a certain amount of inher-
ent random error (imprecision) attributable to testing 
conditions that can vary with such factors as operator 
and reagent used. In the present study, imprecision data 
were obtained from the instrument manufacturers, and 
the combined imprecision of the methods compared 
was used to determine whether differences in values 
obtained could be accounted for solely on the basis of 
inherent random error. Given these acceptability limits, 
we found that disagreement between both PBGMs and 
the automated analyzer could not be explained by in-
herent random error alone. For the PBGM-H, disagree-
ment could be explained partially by proportional bias 
with more deviation at high blood glucose concentra-
tions. We cannot exclude the possibility of proportion-
al bias for the PBGM-D or of constant bias for either 
PBGM. The failure to detect any such bias may have 
been attributable to insufficient statistical power of the 
study caused by not enough samples.
Our third and most important goal was to evaluate 
the clinical usefulness of PBGMs, which was addressed 
by use of error grid analysis. Clinical relevance of 
PBGM measurements was historically assessed by eval-
uating the percentage of PBGM values within 10% of 
the reference value, as recommended by the American 
Diabetes Association.11 The clinical consequence of a 
10% deviation between the reference and measured val-
ues, however, varies on the basis of the absolute blood 
glucose values. The error grid was developed to elimi-
nate this innate variation with the percentage deviation 
method.9,10 Despite statistical evidence of disagreement 
between both PBGMs and the automated analyzer, our 
results indicated that the performance of both PBGMs 
is clinically acceptable. All datum points were in grid 
zone A or B, indicating no effect on clinical outcome. 
We used a human error grid, which, in our judgment, 
is generally well suited to application in dogs; however, 
use of a species-specific error grid may have yielded dif-
ferent results.
Clinicians use the reported results of instrument 
validation, performance statistics, method comparison, 
and other methods when choosing equipment for their 
clinics and when providing clients with advice on the 
purchase of equipment for home use. The prevailing 
opinion in human medicine is that clinical assessment 
that makes use of methods such as the error grid may 
be better than statistical models when comparing meth-
ods.12,13 It is our opinion that both statistical evaluation 
and clinical assessment have value, particularly when 
used together. It is important for veterinary practitio-
ners to understand that any statistical evidence of dis-
agreement between methods must be interpreted in 
light of clinical relevance, bearing in mind such factors 
as intended application of an instrument or clinical de-
cision-making thresholds.
Results of the present study indicated that neither 
PBGM had exact agreement with the automated ana-
lyzer. The PBGM-D values were slightly higher than 
those of the automated analyzer, whereas PBGM-H val-
ues were slightly lower. Although statistical evidence of 
proportional bias was not evident for the PBGM-D, both 
PBGMs had less agreement at high versus low blood 
glucose values. Because error grid analysis revealed this 
lack of agreement would not alter clinical outcome, the 
differences were considered not clinically relevant. This 
finding suggested that, although some bias exists, both 
PBGMs can be used effectively clinically. It also empha-
sized the benefit of consistently using 1 instrument when 
monitoring trends in an animal, as well as the impor-
tance of using instrument-specific reference intervals.
In our study, venous rather than capillary blood 
samples were used. Because of tissue utilization of glu-
cose, postprandial capillary blood glucose concentra-
tions are typically 20% to 25% (20 to 70 mg/dL) higher 
than those of concurrently obtained venous samples.1 
When food is withheld, the difference is much less, 
with capillary blood glucose concentration averaging 
only 2 to 5 mg/dL higher than that of concurrently 
obtained venous blood.1 Dogs in our study were not 
uniform with respect to food withholding or feeding 
prior to sample collection, so it is impossible to pre-
dict the discrepancy between results for capillary and 
venous blood. However, all samples evaluated on all in-
struments were of venous origin, so all methods should 
have been affected similarly. We cannot be certain that 
repeating the study with capillary blood samples would 
yield identical results.
A limitation is that we did not obtain an Hct val-
ue for all dogs at the time of blood glucose analysis. 
Anemia and polycythemia falsely increase or decrease, 
respectively, PBGM measurements.14 Hematocrit data 
were only available for a small subset of dogs, and val-
ues ranged from 25.9% to 59.2% (reference limits, 41% 
to 60%). Because Hct values were not available for all 














dogs, the proportion of anemic or polycythemic dogs 
in the study was unknown and conclusions cannot 
be made about the affect of anemia and polycythemia 
on PBGM performance. All datum points were within 
zone A or B on the error grid, and so the potential ef-
fect of Hct on PBGM values was unlikely to be of clini-
cal importance. Similarly, we did not separately analyze 
blood samples with evidence of hemolysis or lipemia. 
Depending on the method used to measure blood glu-
cose, blood hemoglobin and bilirubin concentrations 
and lipemia can have various effects on assay results.1 
The PBGMs in our study make use of different methods 
of measuring blood glucose concentration and conse-
quently have different innate inaccuracies.
Another limitation of our study was the low num-
ber of hypoglycemic blood samples (6 samples < 70 
mg/dL as measured by the automated analyzer). We 
considered the possibility of creating artifactual hypo-
glycemia by diluting some samples with physiologic sa-
line or delaying separation of plasma, but both methods 
were considered impractical because both PBGMs are 
validated by use of whole blood.
The present study revealed that the PBGM-H 
and PBGM-D are clinically acceptable methods of 
measuring blood glucose concentration in dogs. 
Both require a minute volume of blood and yield re-
sults within seconds. With the PBGM-H, the drop of 
blood must be applied to the test strip, but with the 
PBGM-D, the blood drop is drawn into the test strip 
via capillary action. Capillary action is preferable and 
more practical because it allows use of a lancet ver-
sus a needle and syringe. The advantages of a lancet 
include less restraint, pain, and stress for the animal, 
easier sampling of capillary versus venous blood, and 
improved owner success with home blood glucose 
monitoring.15–17
a. Vacutainer, Becton Dickinson, Franklin Lakes, NJ.
b. Hitachi 911, Roche Diagnostics, Indianapolis, Ind.
c. ACCU-CHEK Active, Roche Diagnostics, Indianapolis, Ind.
d. GlucoPet, Animal Diabetes, Janesville, Wis.
e. Medcalc, version 8.2.1.0, MedCalc Software, Mariakerke, Bel-
gium. Available at: medcalc.be. Accessed Sep 15, 2009.
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